Stockscreener 앱 받기
5.13
0.39%
0.02
시간 외 거래:
5.18
0.05
+0.97%
전일 마감가:
$5.11
열려 있는:
$5.11
하루 거래량:
65,855
Relative Volume:
0.49
시가총액:
$44.18M
수익:
-
순이익/손실:
$-30.18M
주가수익비율:
-1.8377
EPS:
-2.7916
순현금흐름:
$-26.29M
1주 성능:
+1.58%
1개월 성능:
+16.06%
6개월 성능:
-59.70%
1년 성능:
-53.99%
1일 변동 폭
$4.965
$5.35
1주일 범위
$4.90
$5.57
52주 변동 폭
$3.76
$19.35
Atossa Therapeutics Inc Stock (ATOS) Company Profile
명칭
Atossa Therapeutics Inc
전화
206.588.0256
주소
10202 5TH AVENUE NE, SEATTLE, WA
Compare ATOS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
5.13 | 44.00M | 0 | -30.18M | -26.29M | -2.7916 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-01-26 | 개시 | Maxim Group | Buy |
Atossa Therapeutics Inc 주식(ATOS)의 최신 뉴스
Atossa Therapeutics Appoints Two New Medical Directors in Breast Oncology and Rare Diseases - Contract Pharma
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology - GlobeNewswire Inc.
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives - PR Newswire
Should I set a stop loss on Atossa Therapeutics Inc2026 Decliners & Growth Focused Stock Pick Reports - baoquankhu1.vn
Atossa Therapeutics announces launch of early-stage DMD program for rare disease awareness - Traders Union
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference - Sahm
Atossa presents preclinical data on endoxifen for muscular dystrophy - Investing.com South Africa
Atossa presents preclinical data on endoxifen for muscular dystrophy By Investing.com - Investing.com Australia
Atossa Therapeutics, Inc. Presents Clinical Trial Update On Z-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference - marketscreener.com
Atossa Therapeutics shares clinical trial update for Z-endoxifen at MDA conference - Traders Union
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference – Company AnnouncementFT.com - Financial Times
Big Money Moves: Is Atossa Therapeutics Inc a potential multi bagger2026 Price Swings & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Muscle biomarker improvement reported in dystrophic mice, Atossa Therapeutics asserts - Traders Union
Is Atossa Therapeutics Inc likely to announce a buybackJuly 2025 Momentum & Reliable Entry Point Alerts - baoquankhu1.vn
Hedge Fund Moves: Is Atossa Therapeutics Inc stock undervalued right nowJuly 2025 EndofMonth & Long-Term Safe Return Strategies - baoquankhu1.vn
CEO Moves: Is Atossa Therapeutics Inc a speculative investmentQuarterly Market Summary & Smart Swing Trading Alerts - baoquankhu1.vn
Cash from operating activities of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Cash from financing activities of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Free cash flow of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Aug Fed Impact: Is Atossa Therapeutics Inc stock undervalued right nowQuarterly Profit Summary & Daily Growth Stock Investment Tips - baoquankhu1.vn
Total liabilities & shareholders' equities of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Atossa Therapeutics advances Z-endoxifen platform in oncology and DMD targeting molecular precision - Traders Union
ATOS PE Ratio & Valuation, Is ATOS Overvalued - Intellectia AI
Is Atossa Therapeutics Inc. stock influenced by commodity pricesJuly 2025 Recap & Daily Profit Focused Screening - mfd.ru
ATOS Should I Buy - Intellectia AI
ATOS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Atossa Therapeutics outlines Z-Endoxifen strategy for breast cancer prevention - Traders Union
Atossa Therapeutics Launches New $50 Million ATM Program - The Globe and Mail
Atos (ATOS) cuts $100M Jefferies ATM to $0, effective Feb 20, 2026 - Stock Titan
Atossa Genetics Inc. (NASDAQ:ATOS) Receives $95.00 Consensus PT from Analysts - Defense World
Atossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk - The Globe and Mail
Net debt of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Patterns Watch: What is Atossa Therapeutics Incs TAM Total Addressable Market2025 Breakouts & Breakdowns & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Atossa Therapeutics, Inc. Balance Sheet – MUN:YAG - TradingView
Atossa Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Atossa Therapeutics to Participate in UCSF women health event - Traders Union
Basic earnings per share (basic EPS) of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Atossa Therapeutics: Key Developments and Upcoming Catalysts - AD HOC NEWS
Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Up 29.7% in January - Defense World
Is Atossa Therapeutics Inc. likely to announce a buybackJuly 2025 Rallies & Weekly Breakout Watchlists - mfd.ru
Is Atossa Therapeutics Inc. a speculative investmentWeekly Market Report & Free Technical Pattern Based Buy Signals - mfd.ru
Jobs Data: Is Atossa Therapeutics Incs growth already priced inJuly 2025 Price Swings & Stepwise Swing Trade Plans - baoquankhu1.vn
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook - The Malaysian Reserve
Atossa Therapeutics issues letter to shareholders highlighting 2025 accomplishments and 2026 outlook - marketscreener.com
Atossa Therapeutics Issues 2026 Outlook and Strategic Update - TipRanks
Atossa Therapeutics Issues Letter To Shareholders Highlighting 2025 Accomplishments And 2026 Outlook - TradingView
Atossa Therapeutics Issues 2026 Shareholder Letter Highlighting Key Developments - TradingView
Can Atossa Therapeutics Inc. be recession proofJuly 2025 Momentum & Community Consensus Trade Signals - mfd.ru
Atossa Therapeutics launches research program for oral therapy in DMD - Traders Union
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS) and Agilon Health (AGL) - The Globe and Mail
We Think Atossa Therapeutics (NASDAQ:ATOS) Needs To Drive Business Growth Carefully - Yahoo Finance
Atossa Therapeutics Inc (ATOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):